Opinion|Videos|April 14, 2025
Role of Rebiopsy at Disease Progression in EGFRm NSCLC
Panelists discuss how second-line therapy after osimertinib monotherapy depends on resistance mechanisms. If MET amplification, consider MET inhibitors plus EGFR tyrosine kinase inhibitors (TKIs). For C797S mutation, potential options include first- or third-generation EGFR TKI combinations. Chemotherapy remains a key fallback.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Regarding treatment sequencing, how do you approach second-line therapy after osimertinib monotherapy?
Advertisement
Related to this article
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.
Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
OncLive Weekly News Quiz (10/9/2026): Did You Miss Crucial Colon Cancer, Myeloma, Breast Cancer, and Lung Cancer Updates?
4
Next-Generation NAMPT Inhibitors Aim to Revive a Stalled Target in AML and MDS
5